Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fertility drug delivery study pulled before it began

NCT ID NCT07152730

Knowledge-focused Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to see how a hormone called GnRH is processed by the body when given through a small pump (OmniPod) instead of a needle. It was meant for healthy women aged 18 to 40 with regular periods. However, the trial was withdrawn before any participants were enrolled, so no information was gathered.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lutrepulse (gonadotropin-releasing hormone)
What this could lead to
If successful, this could help develop a more convenient way to deliver GnRH for women with certain types of infertility.
What could go wrong
The trial was withdrawn before enrolling anyone, so no data were collected. It is very early-stage research with no results yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Sep 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy female subjects 18 to 40 years old (both included). 2. Body mass index (BMI) between 18 and 30 kg/m2 (both included). 3. Regular menstrual cycles of 24 to 35 days (both included). Exclusion Criteria 1. Any medical condition, which in the judgment of the investigator, may interfere with the absorption, distribution, metabolism, or excretion of gonadotropin-releasing hormone (GnRH). 2. Use of any hormonal contraceptives, growth hormone, insulin or thyroid hormone replacement therapy 30 days prior to dosing in this trial. 3. Previously known or suspected hypersensitivity to GnRH.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amenorrhea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amenorrhea infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amenorrhea Fertility Infertility

Contacts and locations

Locations

  • Ferring Investigational Site

    Miami, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.